For US Healthcare Professionals
XARELTO®: Coronary artery disease (CAD) and peripheral artery disease (PAD) treatment
In the COMPASS trial, the XARELTO® vascular dose* significantly reduced a composite of CV death, MI, and stroke in patients with CAD and/or PAD.†1
The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2
*Patients with coronary syndromes (CAD) and in sinus rhythm.
†Not adjusted for multiplicity.
CAD = coronary artery disease; CV = cardiovascular; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; MI = myocardial infarction; PAD = peripheral artery disease.